Key clinical point: In patients with relapsed/refractory acute myeloid leukemia (AML), mivebresib (MIV) was tolerated and showed antileukemic activity as monotherapy (MIV-mono) and in combination with venetoclax (MIV-Ven).
Major finding: In the MIV-mono cohort, response included complete remission with incomplete blood count recovery (5%) and resistant disease (79%). In patients receiving MIV-Ven, responses were complete remission (7%), partial remission (7%), leukemia-free state (7%), resistant disease (40%), and aplasia (3%). Treatment-emergent adverse events ( TEAEs) were reported in 100% of patients, with serious TEAEs in 74%, 88%, and 40% of patients in MIV-mono, MIV-Ven, and patients who switched from MIV-mono to MIV-Ven groups, respectively.
Study details : Findings are from phase 1 study including 44 adult patients with relapsed/refractory AML who received either MIV-mono (n=19) or MIV-Ven (n=25). Because of disease progression, 5 patients switched from MIV-mono to MIV-Ven.
Disclosures: This study was funded by AbbVie. Investigators including the lead author reported ties with various pharmaceutical companies including AbbVie.
Source: Borthakur G et al. Cancer. 2021 May 2. doi: 10.1002/cncr.33590 .